Effect of dexamethasone on the antileukemic effect of cytarabine: role of deoxycytidine kinase

References

• Nieman, L. K. Pharmacologic Use of Glucocorticoids. UpToDate: Waltham, MA, 2020.
   Google Scholar
• Bergman, A. M.; Pinedo, H. M.; Peters, G. J. Steroids Affect Collateral Sensitivity to Gemcitabine of Multidrug-Resistant Human Lung Cancer Cells. Eur. J. Pharmacol. 2001, 416, 19–24. DOI: 10.1016/S0014-2999(01)00858-5.
   PubMed Web of Science ®Google Scholar
• Herr, I.; Ucur, E.; Herzer, K.; Okouoyo, S.; Ridder, R.; Krammer, P. H.; von Knebel Doeberitz, M.; Debatin, K.-M. Glucocorticoid Cotreatment Induces Apoptosis Resistance toward Cancer Therapy in Carcinomas. Cancer Res. 2003, 63, 3112–3120.
   PubMed Web of Science ®Google Scholar
• Barbour, S. Y. Corticosteroids in the Treatment of Chemotherapy-Induced Nausea and Vomiting. J. Natl. Compr. Canc. Netw. 2012, 10, 493–499. DOI: 10.6004/jnccn.2012.0049.
   PubMed Web of Science ®Google Scholar
• Fietz, E. R.; Keenan, C. R.; López-Campos, G.; Tu, Y.; Johnstone, C. N.; Harris, T.; Stewart, A. G. Glucocorticoid Resistance of Migration and Gene Expression in a Daughter MDA-MB-231 Breast Tumour Cell Line Selected for High Metastatic Potential. Sci. Rep. 2017, 7, 43774. DOI: 10.1038/srep43774.
   PubMed Web of Science ®Google Scholar
• Nakane, T.; Szentendrei, T.; Stern, L.; Virmani, M.; Seely, J.; Kunos, G. Effects of IL-1 and Cortisol on Beta-Adrenergic Receptors, Cell Proliferation, and Differentiation in Cultured Human A549 Lung Tumor Cells. J. Immunol. 1990, 145, 260–266.
   PubMed Web of Science ®Google Scholar
• Croxtall, J. D.; Flower, R. J. Lipocortin 1 Mediates dexamethasone-induced growth arrest of the A549 lung adenocarcinoma cell line . Proc. Natl. Acad. Sci. USA. 1992, 89, 3571–3575. DOI: 10.1073/pnas.89.8.3571.
   PubMed Web of Science ®Google Scholar
• Lu, Y.-S.; Lien, H.-C.; Yeh, P.-Y.; Yeh, K.-H.; Kuo, M.-L.; Kuo, S.-H.; Cheng, A.-L. Effects of Glucocorticoids on the Growth and Chemosensitivity of Carcinoma Cells Are Heterogeneous and Require High Concentration of Functional Glucocorticoid Receptors. World J. Gastroenterol. 2005, 11, 6373–6380. DOI: 10.3748/wjg.v11.i40.6373.
   PubMed Web of Science ®Google Scholar
• Ivarie, R. D.; O'Farrell, P. H. The Glucocorticoid Domain: Steroid-Mediated Changes in the Rate of Synthesis of Rat Hepatoma Proteins. Cell 1978, 13, 41–55. DOI: 10.1016/0092-8674(78)90136-8.
   PubMed Web of Science ®Google Scholar
• Greenstein, S.; Ghias, K.; Krett, N. L.; Rosen, S. T. Mechanisms of Glucocorticoid-Mediated Apoptosis in Hematological Malignancies. Clin. Cancer Res. 2002, 8, 1681–1694.
   PubMed Web of Science ®Google Scholar
• Wei, G.; Twomey, D.; Lamb, J.; Schlis, K.; Agarwal, J.; Stam, R. W.; Opferman, J. T.; Sallan, S. E.; den Boer, M. L.; Pieters, R.; et al. Gene Expression-Based Chemical Genomics Identifies Rapamycin as a Modulator of MCL1 and Glucocorticoid Resistance. Cancer Cell. 2006, 10, 331–342. DOI: 10.1016/j.ccr.2006.09.006.
   PubMed Web of Science ®Google Scholar
• Klein, K.; Haarman, E. G.; de Haas, V.; Zwaan, C. M.; Creutzig, U.; Kaspers, G. L. Glucocorticoid-Induced Proliferation in Untreated Pediatric Acute Myeloid Leukemic Blasts. Pediatr. Blood Cancer 2016, 63, 1457–1460. DOI: 10.1002/pbc.26011.
   PubMed Web of Science ®Google Scholar
• Rowe, J. M. Optimal Induction and Post-Remission Therapy for AML in First Remission. Hematol. Am. Soc. Hematol. Educ. Prog. 2009, 2009, 396–405. DOI: 10.1182/asheducation-2009.1.396.
   Google Scholar
• Cros, E.; Jordheim, L.; Dumontet, C.; Galmarini, C. M. Problems Related to Resistance to Cytarabine in Acute Myeloid Leukemia. Leuk. Lymphoma. 2004, 45, 1123–1132. DOI: 10.1080/1042819032000159861.
   PubMed Web of Science ®Google Scholar
• Wolach, O.; Itchaki, G.; Bar-Natan, M.; Yeshurun, M.; Ram, R.; Herscovici, C.; Shpilberg, O.; Douer, D.; Tallman, M. S.; Raanani, P.; et al. High-Dose Cytarabine as Salvage Therapy for Relapsed or Refractory Acute Myeloid Leukemia—Is More Better or More of the Same? Hematol. Oncol. 2016, 34, 28–35. DOI: 10.1002/hon.2191.
   PubMed Web of Science ®Google Scholar
• Ruiz van Haperen, V. W. T.; Peters, G. J. New Targets for Pyrimidine Antimetabolites for the Treatment of Solid Tumours. Pharm. World Sci. 1994, 16, 104–112. DOI: 10.1007/bf01880661.
   PubMedGoogle Scholar
• Kern, W.; Estey, E. H. High-Dose Cytosine Arabinoside in the Treatment of Acute Myeloid Leukemia: Review of Three Randomized Trials. Cancer 2006, 107, 116–124. DOI: 10.1002/cncr.21543.
   PubMed Web of Science ®Google Scholar
• De Kouchkovsky, I.; Abdul-Hay, M. 'Acute myeloid leukemia: A comprehensive review and 2016 update'. Blood Cancer J. 2016, 6, e441. DOI: 10.1038/bcj.2016.50.
   PubMed Web of Science ®Google Scholar
• Thomas, X.; Dombret, H. Timed-sequential chemotherapy as induction and/or consolidation regimen for younger adults with acute myelogenous leukemia. Hematology 2007, 12, 15–28. DOI: 10.1080/10245330600938240.
   PubMed Web of Science ®Google Scholar
• Plunkett, W.; Liliemark, J. O.; Estey, E.; Keating, M. J. Saturation of ara-CTP Accumulation during High-Dose ara-C Therapy: Pharmacologic Rationale for Intermediate-Dose ara-C. Semin. Oncol. 1987, 14, 159–166.
   PubMed Web of Science ®Google Scholar
• Estey, E.; Plunkett, W.; Dixon, D.; Keating, M.; McCredie, K.; Freireich, E. J. Variables Predicting Response to High Dose Cytosine Arabinoside Therapy in Patients with Refractory Acute Leukemia. Leukemia 1987, 1, 580–583.
   PubMed Web of Science ®Google Scholar
• Peters, G. J.; Jansen, G. Resistance to Antimetabolites. In Principles of Antineoplastic Drug Development and Pharmacology; Schilsky, R. L., Milano, G. A., Ratain, M. P., Eds.; Marcel Dekker, Inc: New York, 1996; pp 543–585.
   Google Scholar
• Malani, D.; Murumägi, A.; Yadav, B.; Kontro, M.; Eldfors, S.; Kumar, A.; Karjalainen, R.; Majumder, M. M.; Ojamies, P.; Pemovska, T.; et al. Enhanced Sensitivity to Glucocorticoids in Cytarabine-Resistant AML. Leukemia 2017, 31, 1187–1195. DOI: 10.1038/leu.2016.314.
   PubMed Web of Science ®Google Scholar
• Bergman, A. M.; Pinedo, H. M.; Talianidis, I.; Veerman, G.; Loves, W. J. P.; van der Wilt, C. L.; Peters, G. J. Increased Sensitivity to Gemcitabine of P-Glycoprotein and Multidrug Resistance-Associated Protein-Overexpressing Human Cancer Cell Lines. Br. J. Cancer 2003, 88, 1963–1970. DOI: 10.1038/sj.bjc.6601011.
   PubMed Web of Science ®Google Scholar
• Bergman, A. M.; Pinedo, H. M.; Jongsma, A. P.; Brouwer, M.; Ruiz van Haperen, V. W.; Veerman, G.; Leyva, A.; Eriksson, S.; Peters, G. J. Decreased Resistance to Gemcitabine (2′,2′-Difluorodeoxycytidine) of Cytosine Arabinoside-Resistant Myeloblastic Murine and Rat Leukemia Cell Lines: Role of Altered Activity and Substrate Specificity of Deoxycytidine Kinase. Biochem. Pharmacol. 1999, 57, 397–406. doi: https://doi.org/10.1016/S0006-2952. (98)00318-9 DOI: 10.1016/S0006-2952(98)00318-9.
   PubMed Web of Science ®Google Scholar
• Hicsonmez, G. The Effect of Steroid on Myeloid Leukemic Cells: The Potential of Short-Course High-Dose Methylprednisolone Treatment in Inducing Differentiation, Apoptosis and in Stimulating Myelopoiesis. Leukemia Res. 2006, 30, 60–68. DOI: 10.1016/j.leukres.2005.05.015.
   PubMed Web of Science ®Google Scholar
• Martens, A. C.; Van Bekkum, D. W.; Hagenbeek, A. The BN Acute Myelocytic Leukemia (BNML) (a Rat Model for Studying Human Acute Myelocytic Leukemia (AML)). Leukemia 1990, 4, 241–257.
   PubMed Web of Science ®Google Scholar
• Hubeek, I.; Comijn, E. M.; Van der Wilt, C. L.; Merriman, R. L.; Padron, J. M.; Kaspers, G. J. L.; Peters, G. J. CI-994 (N-Acetyl-Dinaline) in Combination with Conventional anti-Cancer Agents is Effective against Acute Myeloid Leukemia in Vitro and in Vivo. Oncol. Rep. 2008, 19, 1517–1523. DOI: 10.3892/or.19.6.1517.
   PubMed Web of Science ®Google Scholar
• Veerman, G.; Ruiz van Haperen, V. W. T.; Vermorken, J. B.; Noordhuis, P.; Braakhuis, B. J. M.; Pinedo, H. M.; Peters, G. J. Antitumor Activity of Prolonged as Compared with Bolus Administration of 2’,2’-Difluorodeoxycytidine in Vivo against Murine Colon. Cancer Chemother. Pharmacol. 1996, 38, 335–342. DOI: 10.1007/s002800050492.
   PubMed Web of Science ®Google Scholar
• Peters, G. J.; Laurensse, E. J.; Leyva, A.; Pinedo, H. M. Tissue Homogenization Using a Micro-Dismembrator for the Measurement of Enzyme Activities. Clin. Chim. Acta 1986, 158, 193–198. doi: https://doi.org/10.1016/0009-8981. (86)90236-6 DOI: 10.1016/0009-8981(86)90236-6.
   PubMed Web of Science ®Google Scholar
• Ruiz van Haperen, V. W. T.; Veerman, G.; Braakhuis, B. J. M.; Vermorken, J. B.; Boven, E.; Leyva, A.; Peters, G. J. Deoxycytidine Kinase and Deoxycytidine Deaminase Activities in Human Tumour Xenografts. Eur. J. Cancer 1993, 29, 2132–2137. doi: https://doi.org/10.1016/0959-8049. (93)90048-K DOI: 10.1016/0959-8049(93)90048-K.
   Google Scholar
• Eriksson, S.; Kierdaszuk, B.; Munch-Petersen, B.; Oberg, B.; Johansson, N. G. Comparison of the Substrate Specificities of Human Thymidine Kinase 1 and 2 and Deoxycytidine Kinase toward Antiviral and Cytostatic Nucleoside Analogs. Biochem. Biophys. Res. Commun. 1991, 176, 586–592. doi: https://doi.org/10.1016/S0006-291X. (05)80224-4 DOI: 10.1016/S0006-291X(05)80224-4.
   PubMed Web of Science ®Google Scholar
• Peters, G. J.; Clavel, M.; Noordhuis, P.; Geyssen, G. J.; Laan, A. C.; Guastalla, J.; Edzes, H. T.; Vermorken, J. B. Clinical Phase I and Pharmacology Study of Gemcitabine (2', 2'-Difluorodeoxycytidine) Administered in a Two-Weekly Schedule. J. Chemother. 2007, 19, 212–221. DOI: 10.1179/joc.2007.19.2.212.
   PubMed Web of Science ®Google Scholar
• Spasokoukotskaja, T.; Sasvári-Székely, M.; Keszler, G.; Albertioni, F.; Eriksson, S.; Staub, M. Treatment of Normal and Malignant Cells with Nucleoside Analogues and Etoposide Enhances Deoxycytidine Kinase Activity. Eur. J. Cancer 1999, 35, 1862–1867. doi: https://doi.org/10.1016/S0959-8049. (99)00223-3 DOI: 10.1016/S0959-8049(99)00223-3.
   PubMed Web of Science ®Google Scholar
• Csapó, Z.; Sasvári-Székely, M.; Spasokoukotskaja, T.; Staub, M. Modulation of Human Deoxycytidine Kinase Activity as a Response to Cellular Stress Induced by NaF. Acta Biochim. Pol. 2001, 48, 251–256. DOI: 10.18388/abp.2001_5133.
   PubMed Web of Science ®Google Scholar
• Sigmond, J.; Bergman, A. M.; Leon, L. G.; Loves, W. J. P.; Hoebe, E. K.; Peters, G. J. Staurosporine Increases Toxicity of Gemcitabine in Non-Small Cell Lung Cancer Cells: Role of Protein Kinase C, Deoxycytidine Kinase and Ribonucleotide Reductase. Anticancer. Drugs. 2010, 21, 591–599. DOI: 10.1097/CAD.0b013e32833a3543.
   PubMed Web of Science ®Google Scholar
• Smal, C.; Cardoen, S.; Bertrand, L.; Delacauw, A.; Ferrant, A.; Van den Berghe, G.; Van Den Neste, E.; Bontemps, F. Activation of Deoxycytidine Kinase by Protein Kinase Inhibitors and Okadaic Acid in Leukemic Cells. Biochem. Pharmacol. 2004, 68, 95–103. doi: . DOI: 10.1016/j.bcp.2004.02.031.
   PubMed Web of Science ®Google Scholar